FDA approves Xeljanz for rheumatoid arthritis

Author(s):

On Nov. 6, the U.S. Food and Drug Administration (FDA) approved Xeljanz (tofacitinib) to treat adults with moderately to severely active rheumatoid arthritis who have had an inadequate response to, or who are intolerant of, methotrexate. Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here